Latest Ari Melnick Stories
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses.
New insight into the aggressive behavior of certain adult B-acute lymphoblastic leukemias has provided researchers with a potential new prognostic biomarker and a promising new therapeutic target.
A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL).
One major obstacle in the fight against cancer is that anticancer drugs often affect normal cells in addition to tumor cells, resulting in significant side effects.
Doctors who treat children with the most common form of childhood cancer â€“ acute lymphoblastic leukemia â€“ are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern cancer drugs.
Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults.
Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells.
Scientists are one step closer to developing a targeted therapy for lymphoma.
Upcoming clinical trial will test compound in patients.
- totally perplexed and mixed up.